+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07769151

BIO-FUNCTION Study Evaluating Biological and Functional Tests to Predict Non-Relapse Mortality in Stem Cell Transplant and Cell Therapy

Led by Henry Ford Health System · Updated on 2026-10-19

124

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether a combination of physical tests and blood tests conducted before stem cell transplant and cell therapy SCTCT can predict the risk of non-relapse mortality NRM, which means death not related to disease return. This observational study aims to assess biological and functional reserves to better understand factors that could affect outcomes after SCTCT. Participants will undergo standard physical function assessments such as Instrumental Activities of Daily Living IADL, hand grip strength, and walking tests like the Timed Up and Go TUG. Blood samples will be collected as part of routine care to measure markers including LDH, albumin, ferritin, CRP, platelet count, and creatinine. Additionally, a special blood test to measure CXCL9, not part of standard care, will be drawn before SCTCT. During the study, participants will be monitored to measure non-relapse mortality at day 100 and one year after treatment. The research team will collect and analyze physical and blood test data to evaluate their ability to predict NRM. The total study duration extends until December 2031, with primary outcome assessment by the end of 2030.

CONDITIONS

Brief Title

BIO-FUNCTION for Prediction Non Relapse Mortality in Transplant and Cell Therapy

Research Team

S

Shatha Farhan, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here